Ivermectin News and Research

RSS
Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
WHO experts update guidance on COVID-19 treatments

WHO experts update guidance on COVID-19 treatments

New analysis of Indonesia Wolbachia trial shows potential for greater dengue reduction

New analysis of Indonesia Wolbachia trial shows potential for greater dengue reduction

Few firm beliefs and low trust: Americans not sure what’s true in age of health misinformation

Few firm beliefs and low trust: Americans not sure what’s true in age of health misinformation

COVID-19 misinformation spread on social media by US physicians

COVID-19 misinformation spread on social media by US physicians

FDA head Robert Califf battles misinformation — sometimes with fuzzy facts

FDA head Robert Califf battles misinformation — sometimes with fuzzy facts

How a combination of covid lawsuits and media coverage keeps misinformation churning

How a combination of covid lawsuits and media coverage keeps misinformation churning

Metformin shows promising antiviral activity against SARS-CoV-2

Metformin shows promising antiviral activity against SARS-CoV-2

Metformin reduces risk of long COVID by over 40%

Metformin reduces risk of long COVID by over 40%

Common diabetes drug prevents the development of long COVID, study finds

Common diabetes drug prevents the development of long COVID, study finds

Do COVID-19 drugs in aquatic matrices negatively impact microalgae and cyanobacteria communities?

Do COVID-19 drugs in aquatic matrices negatively impact microalgae and cyanobacteria communities?

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

The policy, and politics, of Medicare Advantage

The policy, and politics, of Medicare Advantage

Early outpatient treatment of COVID-19 with metformin could reduce the risk of developing long COVID

Early outpatient treatment of COVID-19 with metformin could reduce the risk of developing long COVID

High-dose ivermectin does not reduce COVID-19 symptom duration among mild-to-moderate outpatients

High-dose ivermectin does not reduce COVID-19 symptom duration among mild-to-moderate outpatients

Senators have mental health crises, too

Senators have mental health crises, too

What are the predictors of in-hospital mortality in cancer patients with COVID-19?

What are the predictors of in-hospital mortality in cancer patients with COVID-19?

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

New survey shows increase in COVID-19 vaccine acceptance across 23 countries in 2022

New survey shows increase in COVID-19 vaccine acceptance across 23 countries in 2022

Can ivermectin improve the duration of sustained recovery among COVID-19 outpatients?

Can ivermectin improve the duration of sustained recovery among COVID-19 outpatients?

Study finds a lower compliance rate with recently released guidelines for COVID-19 care

Study finds a lower compliance rate with recently released guidelines for COVID-19 care